In the present study, we failed to detect a correlation between MXD3 expression and survival prognosis of BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, KIRP, LAML, LUSC PRAD, THYM, UCEC, or UCS patients; hence, the current TCGA clinical data-based evidence cannot support the role of MXD3 overexpression in the clinical prognosis of those cancers. The gene discussed is MXD3; the disease is cancer.